+
Home
+
Contact
Profile
Management
Directors
Mission & Values
Awards & Recognition
Contact Us
Directions
Overview
Somatic Cell Therapies »
Overview
LG690 (GVHD)
LG768 (CLL)
LG740
Stem Cell Therapies »
Overview
LG631 (Glioma)
LG889 (Hemophilia)
Vaccines »
Overview
LG611 (Pandemic Flu)
LG811 (Seasonal Flu)
LG912 (Hepatitis C Virus)
LG970 (HIV/AIDS)
Protein Therapeutics »
Overview
LG747 (Anemia)
LG888 (Hemophilia)
Contact Us
Clinical Trials
Trials open for enrollment
Patient's Library »
Disease Information
What are clinical trials?
Glossary
Business Strategy
Business Model
Therapeutic Pipeline
Partnerships
Intellectual Property
Contact Us
Press Releases
Media Kit
Contact Us
Why Lentigen?
Positions Open
Contact Us
Tim Ravenscroft, CEO of Lentigen, discusses a new partnership with IAVI on AIDS vaccine research and development at a Congressional Biomedical Research Caucus briefing in Washington DC on April 23.
Read more
.
Lentigen Awarded Phase II SBIR Grant for Clinical Development of TCR Immunotherapy Targeted to Melanoma [pdf]
Lentigen Awarded Phase I STTR Grant For Hunter Syndrome [pdf]
IAVI and Lentigen to Collaborate on Design of Novel AIDS Vaccine Candidate [pdf]
Lentigen Awarded Phase I SBIR Grant for Hepatitis C Vaccine [pdf]
Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement [pdf]
Lentigen Corporation and PATH Announce Partnership on Innovative Vaccine for Pandemic Influenza [pdf]
© Copyright 2008 Lentigen Corp. All Rights Reserved.
+
Privacy Policy
+
Terms of Use